125 related articles for article (PubMed ID: 11507721)
1. Association and aggregation analysis using kin-cohort designs with applications to genotype and family history data from the Washington Ashkenazi Study.
Chatterjee N; Shih J; Hartge P; Brody L; Tucker M; Wacholder S
Genet Epidemiol; 2001 Sep; 21(2):123-38. PubMed ID: 11507721
[TBL] [Abstract][Full Text] [Related]
2. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA
Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399
[TBL] [Abstract][Full Text] [Related]
3. Case-control and case-only designs with genotype and family history data: estimating relative risk, residual familial aggregation, and cumulative risk.
Chatterjee N; Kalaylioglu Z; Shih JH; Gail MH
Biometrics; 2006 Mar; 62(1):36-48. PubMed ID: 16542227
[TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
5. Pseudo-likelihood estimates of the cumulative risk of an autosomal dominant disease from a kin-cohort study.
Moore DF; Chatterjee N; Pee D; Gail MH
Genet Epidemiol; 2001 Feb; 20(2):210-27. PubMed ID: 11180447
[TBL] [Abstract][Full Text] [Related]
6. A marginal likelihood approach for estimating penetrance from kin-cohort designs.
Chatterjee N; Wacholder S
Biometrics; 2001 Mar; 57(1):245-52. PubMed ID: 11252606
[TBL] [Abstract][Full Text] [Related]
7. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
King MC; Marks JH; Mandell JB;
Science; 2003 Oct; 302(5645):643-6. PubMed ID: 14576434
[TBL] [Abstract][Full Text] [Related]
8. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
Simchoni S; Friedman E; Kaufman B; Gershoni-Baruch R; Orr-Urtreger A; Kedar-Barnes I; Shiri-Sverdlov R; Dagan E; Tsabari S; Shohat M; Catane R; King MC; Lahad A; Levy-Lahad E
Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3770-4. PubMed ID: 16537453
[TBL] [Abstract][Full Text] [Related]
9. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
[TBL] [Abstract][Full Text] [Related]
10. Adjustment for competing risk in kin-cohort estimation.
Chatterjee N; Hartge P; Wacholder S
Genet Epidemiol; 2003 Dec; 25(4):303-13. PubMed ID: 14639700
[TBL] [Abstract][Full Text] [Related]
11. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
12. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
14. Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer.
Steinmann D; Bremer M; Rades D; Skawran B; Siebrands C; Karstens JH; Dörk T
Br J Cancer; 2001 Sep; 85(6):850-8. PubMed ID: 11556836
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 and sex ratio.
Struewing JP; Hartge P; Wacholder S; Tucker MA; Greene MH
Eur J Hum Genet; 2004 Aug; 12(8):663-7. PubMed ID: 15114373
[TBL] [Abstract][Full Text] [Related]
16. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000.
Tryggvadottir L; Sigvaldason H; Olafsdottir GH; Jonasson JG; Jonsson T; Tulinius H; Eyfjörd JE
J Natl Cancer Inst; 2006 Jan; 98(2):116-22. PubMed ID: 16418514
[TBL] [Abstract][Full Text] [Related]
17. Designing studies to estimate the penetrance of an identified autosomal dominant mutation: cohort, case-control, and genotyped-proband designs.
Gail MH; Pee D; Benichou J; Carroll R
Genet Epidemiol; 1999; 16(1):15-39. PubMed ID: 9915565
[TBL] [Abstract][Full Text] [Related]
18. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N
Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604
[TBL] [Abstract][Full Text] [Related]
19. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.
Wang WW; Spurdle AB; Kolachana P; Bove B; Modan B; Ebbers SM; Suthers G; Tucker MA; Kaufman DJ; Doody MM; Tarone RE; Daly M; Levavi H; Pierce H; Chetrit A; Yechezkel GH; Chenevix-Trench G; Offit K; Godwin AK; Struewing JP
Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):955-60. PubMed ID: 11535547
[TBL] [Abstract][Full Text] [Related]
20. Optimal designs for estimating penetrance of rare mutations of a disease-susceptibility gene.
Gong G; Whittemore AS
Genet Epidemiol; 2003 Apr; 24(3):173-80. PubMed ID: 12652521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
